Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.

Science translational medicine - 21 Sept 2022

Liang Jackson, Ingalla Ellen Rei, Yao Xiaosai, Wang Bu-Er, Tai Lisa, Giltnane Jennifer, Liang Yuxin, Daemen Anneleen, Moore Heather M, Aimi Junko, Chang Ching-Wei, Gates Mary R, Eng-Wong Jennifer, Tam Lucinda, Bacarro Natasha, Roose-Girma Merone, Bellet Meritxell, Hafner Marc, Metcalfe Ciara

Abstract excerpt

ESR1 (estrogen receptor 1) hotspot mutations are major contributors to therapeutic resistance in estrogen receptor-positive (ER+) breast cancer. Such mutations confer estrogen independence to ERα, providing a selective advantage in the presence of estrogen-depleting aromatase inhibitors. In addition, ESR1 mutations reduce the potency of tamoxifen and fulvestrant, therapies that bind ERα directly. These...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors
Share to Estrogen Receptor alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogens

Share to Fulvestrant

Share to Progesterone

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Tamoxifen

Source

Identifiers

PMID: 36130016
DOI: 10.1126/scitranslmed.abo5959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.PMID 36130016Read ↗

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Semantic proximity Read ↗

Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα−positive breast cancerSemantic proximity Read ↗

Influence of Estrogen Treatment On ESR1+ and ESR1- Cells In ER+ Breast Cancer: Insights From Single-Cell Analysis of Patient-Derived Xenograft ModelsSemantic proximity Read ↗

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Semantic proximity Read ↗

Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer.Semantic proximity Read ↗

ESR1 activating mutations: From structure to clinical application.Semantic proximity Read ↗

Pushing estrogen receptor around in breast cancerSemantic proximity Read ↗

Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.Semantic proximity Read ↗

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast CancerSemantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signalingSemantic proximity Read ↗

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.